Abcam, ab216192, Recombinant mouse PD-L1 protein (Fc Chimera)

Size: 100µg
Recombinant mouse PD-L1 protein (Fc Chimera) is a Mouse Fragment protein, in the 19 to 238 aa range, expressed in HEK 293 cells, with >90%, suitable for SDS-PAGE.
Key facts
Purity:>90% SDS-PAGE,
Expression system:HEK 293 cells,
Tags:Tag free,
Applications:SDS-PAGESee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Biologically active:Yes,
Biological activity:Active,
Accession:Q9EP73,
Animal free:No,
Carrier free:No,
Species:Mouse,
Storage buffer:pH: 7.4Constituents: Phosphate Buffer, 20% Glycerol (glycerin, glycerine), 0.64% Sodium chloride, 0.02% Potassium chloride

Product details:
Useful for the study of protein-protein interaction and
in vitro
in vivo
protein function studies.
Storing diluted protein is not recommended, if necessary, use carrier protein (BSA 0.1 – 0.5%).

Properties and Storage Information:
Shipped at conditions-Blue Ice, Appropriate short-term storage conditions--80°C, Appropriate long-term storage conditions--80°C, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
PD-L1 also known as Programmed Death-Ligand 1 or CD274 is a protein involved in immune modulation. Mechanically PD-L1 interacts with its receptors particularly PD-1 to regulate cellular immune responses. This transmembrane protein has a calculated molecular weight of approximately 33 kDa. PD-L1 is expressed on various cell types including tumor cells and immune cells such as dendritic cells macrophages and B cells. Its expression is often upregulated in response to inflammatory cytokines.
Biological function summary
PD-L1 plays a central role in immune evasion mechanisms utilized by tumors. It is not part of a larger protein complex but directly interacts with PD-1 and CD80. When PD-L1 binds to PD-1 it sends inhibitory signals leading to decreased T cell activation and proliferation allowing cancer cells to avoid immune destruction. PD-L1 expression provides a mechanism for tumors to suppress immune surveillance facilitating tumor progression.
Pathways
PD-L1 is integral to the immune checkpoint pathway which is an important regulator of immune response. The interaction between PD-L1 and PD-1 provides a mechanism for immune tolerance which is part of the broader adaptive immune system pathway. PD-L1 is related to other immune checkpoint proteins such as CTLA-4 in its function to limit autoreactivity and promote immune homeostasis.
PD-L1 is most associated with cancer particularly in tumors such as melanoma and non-small cell lung cancer. PD-L1 expression on tumor cells often correlates with poor prognosis. PD-L1 directly interacts with PD-1 in these cancers a target for immunotherapies such as checkpoint inhibitors which aim to block this interaction and restore immune activity against tumors. PD-L1 involvement extends to autoimmune disorders where altered expression can impact tolerance and lead to immune-related tissue damage.